ANTI-KRATOM ASSOCIATION

Rep. Tim Turner has identified a real problem: potent kratom-derived compounds are appearing in Oklahoma retail commerce and state officials are linking them to a growing number of deaths. But a molecule-by-molecule ban that leaves kratom and its mitragynine supply chain untouched stops one step too soon.

1. Oklahoma Is Building a Gate Without a Fence

Turner's proposal is aimed at a serious problem. The Oklahoma House says the Office of the Chief Medical Examiner reported 38 deaths from January through June 2026 involving one of the identified compounds alone, plus another 73 deaths involving at least one of the compounds with another intoxicating drug or substance.

But Oklahoma's proposed answer has an obvious structural weakness: it targets selected compounds at the end of the pipeline while leaving kratom—the plant that supplies mitragynine and the broader commercial alkaloid supply chain—legal.

2. The Source-Material Problem Is Not Rhetoric. It Is Chemistry.

Mitragynine is the principal alkaloid associated with kratom. Oklahoma's existing KCPA expressly defines legal kratom leaf and extracts and regulates the alkaloid composition of products sold in the state.

DEA's 2026 Schedule I order describes the next step plainly: commercial products have proliferated containing opioids chemically synthesized from mitragynine or 7-hydroxymitragynine. DEA says the chemical scaffolds of mitragynine or 7-OH were used to develop MP, MGM-15 and MGM-16 through chemical modification of purified isolates.

That does not mean somebody pours a bag of raw leaf into a beaker and gets MGM-15. It means the commercial kratom alkaloid supply chain provides the upstream chemistry from which these newer compounds can be made.

3. MGM-15 Shows Exactly How This Works

The scientific literature makes the relationship unusually concrete. A published synthesis of MGM-15 starts with 7-hydroxymitragynine. Researchers chemically reduced 7-OH and produced MGM-15.

DEA likewise identifies MGM-15 as a derivative of 7-OH and mitragynine pseudoindoxyl as a chemical rearrangement product of 7-OH.

4. Oklahoma Already Tried the KCPA Theory

Oklahoma is not approaching kratom from a blank sheet of paper. The state already adopted a Kratom Consumer Protection Act. It defines acceptable kratom products, establishes composition rules and permits a regulated retail market.

Yet the state is back at the Capitol because the market evolved faster than the statute.

Oklahoma Bureau of Narcotics Director Donnie Anderson put the enforcement problem in unusually stark terms. Because the products Turner is targeting are not currently controlled dangerous substances under Oklahoma law, Anderson said his agency does not have jurisdiction to investigate and shut down their suppliers.

5. Turner Is Right About the Convenience Store

Turner's strongest point should become the premise of the entire debate: “It is time to stop treating this like just another product on a convenience store shelf.”

Correct. Then Oklahoma should follow that principle to its logical conclusion.

Do not remove three compounds and declare the shelf fixed. Do not assume today's statutory list will control tomorrow's chemistry. And do not preserve an ordinary retail market in kratom and mitragynine-rich extracts without asking whether that upstream supply chain is part of the problem lawmakers are now trying to solve.

6. Scheduling Three Molecules Does Not End a Designer-Drug Market

Schedule I placement can give law enforcement authority over the substances that are actually scheduled. That matters.

But molecule-specific scheduling has a built-in limitation. Chemistry is not required to stop where a statute stops. Change the molecule, market the replacement, wait for toxicology and law enforcement to catch up, and eventually lawmakers are back in session adding another name.

DEA's federal action reflects how quickly this market has evolved: MP and MGM-15 moved from research compounds into commercial products, while forensic laboratories have had to develop methods and reference standards capable of identifying them.

7. The Question Oklahoma Lawmakers Should Have to Answer

The central question is not whether MP or MGM-15 should be Schedule I. Oklahoma can evaluate those compounds under its controlled-substance law.

The Oklahoma KCPA Experiment Has Already Answered Something

Oklahoma tried regulation. It defined acceptable kratom. It established chemical limits. It permitted a retail market.

Now state officials are reporting escalating deaths involving kratom-related compounds, the narcotics bureau says it needs additional authority, and lawmakers are preparing to schedule a new list of substances.

Turner deserves credit for recognizing that Oklahoma has a serious problem. But if the Legislature bans three names while preserving the upstream commercial source of the chemistry, it will have built another gate in the same open field.